Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ZY7X
|
|||
| Former ID |
DNC010259
|
|||
| Drug Name |
GNF-PF-2094
|
|||
| Synonyms |
GNF-Pf-2094; CHEMBL578928; AC1LF3VX; ChemDiv3_003176; MLS000555549; REGID_for_CID_697226; ZINC73452; MolPort-002-569-783; HMS2595H06; HMS3382F08; HMS1482A08; DNDI1388215; CCG-20329; BDBM50304834; STK839621; AKOS005624964; MCULE-1058130285; IDI1_021086; SMR000147266; SR-01000110418; SR-01000110418-1; BRD-K84805375-001-01-1; N2-benzyl-N4-cyclohexyl-6-methylpyrimidine-2,4-diamine; 2-N-benzyl-4-N-cyclohexyl-6-methylpyrimidine-2,4-diamine; N*2*-Benzyl-N*4*-cyclohexyl-6-methyl-pyrimidine-2,4-diamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H24N4
|
|||
| Canonical SMILES |
CC1=CC(=NC(=N1)NCC2=CC=CC=C2)NC3CCCCC3
|
|||
| InChI |
1S/C18H24N4/c1-14-12-17(21-16-10-6-3-7-11-16)22-18(20-14)19-13-15-8-4-2-5-9-15/h2,4-5,8-9,12,16H,3,6-7,10-11,13H2,1H3,(H2,19,20,21,22)
|
|||
| InChIKey |
GDKCAAWSNQLXNX-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Debrisoquine 4-hydroxylase (CYP2D6) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Metabolism of xenobiotics by cytochrome P450 | |||
| Drug metabolism - cytochrome P450 | ||||
| Serotonergic synapse | ||||
| Reactome | Xenobiotics | |||
| WikiPathways | Metapathway biotransformation | |||
| Tamoxifen metabolism | ||||
| Oxidation by Cytochrome P450 | ||||
| Vitamin D Receptor Pathway | ||||
| Aripiprazole Metabolic Pathway | ||||
| Fatty Acid Omega Oxidation | ||||
| Codeine and Morphine Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines. Bioorg Med Chem Lett. 2010 Jan 1;20(1):228-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.